A 52-year-old woman with inadequately controlled rheumatoid arthritis comes to the clinic. Her physician is considering starting her on a newly approved oral Janus kinase (JAK) inhibitor. Before prescribing the medication, the physician reviews the published results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial that evaluated the safety and efficacy of the drug over a 52-week period.
The trial enrolled a total of patients who were randomized in a 1:1 ratio to receive either the JAK inhibitor or a placebo. The safety data regarding incident herpes zoster infections during the trial are summarized in the table below:
| Group | Total Patients | Herpes Zoster Cases |
|---|---|---|
| JAK Inhibitor | 750 | 45 |
| Placebo | 750 | 15 |
Based on these study results, what is the number needed to harm (NNH) for a herpes zoster infection?
Answer: 25